Los puntos clave no están disponibles para este artículo en este momento.
The administration of TG4010 was generally well tolerated in patients with metastatic tumors, and transient disease stabilization was observed in several patients, warranting further clinical studies with the product.
Rochlitz et al. (Mon,) studied this question.